Category

Lundbeckfonden Ventures
CAMBRIDGE, Mass., Feb. 04, 2019 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections, today announced the acceptance by the U.S. Food and Drug Administration (FDA) of its Investigational New Drug (IND) application for SPR994,...
Lund, Sweden, 08.00 CET, 1 February 2019 – BONESUPPORT, an emerging leader in orthobiologics for the management of bone voids, today announces two oral presentations, and three poster presentations at the upcoming Orthopaedic Research Society (ORS) 2019 Annual Meeting. The meeting takes place from February 2-5 at the Austin Convention Center in Austin, Texas and...
Advancing FUROSCIX® with the SmartDose® Drug Delivery System – Forecast 2018 year-end cash of $82 – $87 million and 2019 expenditures of $8 – $10 million per quarter BURLINGTON, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) — scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of...
Cambridge, UK and Indianapolis, US – 28 January 2019: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”) (EURONEXT: ACPH) welcomes an editorial published in the leading peer-reviewed journal Anesthesiology, accompanying the print publication of results from its positive Phase 3 clinical trial of BARHEMSYS™ (intravenous amisulpride) as rescue treatment of established post-operative nausea & vomiting...
CAMBRIDGE, Mass., Jan. 07, 2019 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections, and Everest Medicines announced today that they have entered into a collaboration to develop, manufacture and commercialize SPR206 in Greater China, South Korea and certain...
CAMBRIDGE, Mass. Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that it has received written confirmation from the U.S. Food and Drug Administration (FDA) regarding agreement on the design of its Phase 3 registration trials designed to evaluate light-activated AU-011 for the treatment of patients with choroidal...
Lund, Sweden, 8:00 CET, January 4 2019 – BONESUPPORT™ an emerging leader in Orthobiologics for the management of bone voids, announces changes in its leadership team that will take place March 1, 2019. Annelie Aava Vikner starts in a new position as the company´s Executive Vice President Global Marketing & Communications. Annelie Aava Vikner has...
January 3, 2019 Tiburio raises $31M in a Series A round to advance two clinical stage compounds TBR-760, for the treatment of nonfunctioning pituitary adenoma (NFPA), and TBR-065 for rare endocrine diseases Tiburio appoints Abraham N. Ceesay as Chief Executive Officer Cambridge, MA, January 3, 2019 – Cydan today announced the launch of Tiburio Therapeutics Inc....
Det nystartede amerikanske selskab Tiburio, der er i gang med at udvikle et middel mod sjældne tumorer tæt ved hypofysen, henter en samlet investering på godt 200 mio. kr. – bl.a. fra Lundbeckfonden Ventures. Lundbeckfonden Ventures har – sammen med en række andre investorer – investeret i alt 200 mio. kr. i det nystartede Tiburio....
Lund, Sweden, 18:00 CET 28 December 2018 – During December, the number of shares and votes in BONESUPPORT HOLDING AB (publ) has increased due to the exercise of warrants. As of 28 December 2018, the number of shares and votes in BONESUPPORT HOLDING AB (publ) amounts to 51,795,917. For more information contact: BONESUPPORT AB Emil...
1 2 3 44

Nyheder

Danske forskere bringer nyt om overvældende søvntrang 
19. februar 2019
Hidtil største studie knytter såkaldt kattelort-parasit til skizofreni
2. februar 2019
Forskere finder sammenhænge mellem psykiatriske lidelser og begivenheder i fostertilstanden
28. januar 2019

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge